Venmax Drugs

{
  "main_header": {
    "sid": 225982,
    "name": "Venmax Drugs",
    "stock_name": "Venmax Drugs",
    "full_name": "Venmax Drugs & Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/venmax-drugs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "24.00",
    "chg": -0.06,
    "chgp": "-0.25%",
    "dir": -1,
    "prev_price": "24.06",
    "mcapval": "29.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531015,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE154G01022",
    "curr_date": "May 08",
    "curr_time": "",
    "bse_nse_vol": "271 ",
    "exc_status": "Active",
    "traded_date": "May 08, 2026",
    "traded_date_str": "2026 05 08",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/venmax-drugs-225982-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "When is the next results date for Venmax Drugs & Pharmaceuticals Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-venmax-drugs-pharmaceuticals-ltd-3980408",
        "imagepath": "",
        "date": "2026-05-07 23:16:30",
        "description": "The next results date for Venmax Drugs & Pharmaceuticals Ltd is scheduled for 14 May 2026...."
      },
      {
        "title": "Venmax Drugs & Pharmaceuticals Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venmax-drugs-pharmaceuticals-ltd-is-rated-strong-sell-3970017",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/VenmaxDrugsPhar_mojoScore_3970017.png",
        "date": "2026-04-30 10:10:20",
        "description": "Venmax Drugs & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook."
      },
      {
        "title": "Why is Venmax Drugs & Pharmaceuticals Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-venmax-drugs-pharmaceuticals-ltd-fallingrising-3848975",
        "imagepath": "",
        "date": "2026-02-21 01:00:00",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Price Movement and Market Comparison</strong></p>\n<p>Venmax Drugs’ recent price action has been notably weaker compared to the benchmark Sensex. Over the past week, the stock has declined by 3.67%, while the Sensex gained 0.23%. Similarly, in the last month, Venmax Drugs marginally fell by 0.46%, whereas the Sensex rose by 0.77%. This underperformance is further emphasised by the stock’s three-day consecutive fall, during which it lost approximately 4.7% of its value. Such a trend indicates a short-term bearish sentiment among investors.</p>\n<p>Despite these recent setbacks, the stock has delivered a positive return of 4.13% year-to-date, outperforming the Sensex which is down 2.82% in the same period. Over the last year, Venmax Drugs has appreciated by 6.96%, though this is sligh..."
      },
      {
        "title": "Venmax Drugs & Pharmaceuticals Downgraded to Strong Sell Amid Technical and Financial Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venmax-drugs-pharmaceuticals-downgraded-to-strong-sell-amid-technical-and-financial-concerns-3843606",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenmaxDrugsPhar_mojoScore_3843606.png",
        "date": "2026-02-17 08:06:13",
        "description": "Venmax Drugs & Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Feb 2026, reflecting deteriorating technical indicators and stagnant financial performance. The company’s Mojo Score has slipped to 17.0, signalling heightened risk for investors amid a challenging market environment and weakening fundamentals."
      },
      {
        "title": "Venmax Drugs Falls 4.36%: 3 Key Factors Driving the Weekly Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venmax-drugs-falls-436-3-key-factors-driving-the-weekly-decline-3841072",
        "imagepath": "",
        "date": "2026-02-15 13:00:06",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>09 Feb:</strong> Q3 FY26 results reveal revenue growth but wafer-thin margins and governance concerns</p>\n                    <p><strong>10 Feb:</strong> Quality grade downgraded to below average with a Sell rating assigned</p>\n                    <p><strong>10 Feb:</strong> Mixed technical signals emerge amid flat financial performance</p>\n                    <p><strong>13 Feb:</strong> Week closes at Rs.26.97, down 4.36%, underperforming Sensex</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.28.20</div></div>\n                    <div class=\"stat-item\">..."
      },
      {
        "title": "Venmax Drugs & Pharmaceuticals Ltd Downgraded to Sell Amidst Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/venmax-drugs-pharmaceuticals-ltd-downgraded-to-sell-amidst-mixed-financial-and-technical-signals-3829883",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenmaxDrugsPhar_mojoScore_3829883.png",
        "date": "2026-02-10 08:05:57",
        "description": "Venmax Drugs & Pharmaceuticals Ltd has been assigned a Sell rating with a Mojo Score of 33.0, reflecting a downgrade from its previous ungraded status. This change, effective from 09 Feb 2026, is driven by deteriorating quality metrics, challenging financial trends, and a cautious technical outlook, signalling increased risk for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Venmax Drugs & Pharmaceuticals Ltd Quality Grade Downgrade: A Detailed Fundamental Analysis",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/venmax-drugs-pharmaceuticals-ltd-quality-grade-downgrade-a-detailed-fundamental-analysis-3829432",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/VenmaxDrugsPhar_qualitydot_3829432.png",
        "date": "2026-02-10 08:00:09",
        "description": "Venmax Drugs & Pharmaceuticals Ltd has recently undergone a significant downgrade in its quality grading, shifting from a non-rated status to a below average rating as of 9 February 2026. This change reflects a reassessment of the company’s core financial health and operational consistency, raising concerns about its long-term investment appeal despite some strong sales growth. This article delves into the key financial metrics and business fundamentals that have influenced this downgrade, providing investors with a comprehensive understanding of the company’s current standing within the Pharmaceuticals & Biotechnology sector."
      }
    ],
    "total": 80,
    "sid": "225982",
    "stock_news_url": "https://www.marketsmojo.com/news/venmax-drugs-pharmaceuticals-225982"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Audited Standalone Financial Results Of The Company For The Quarter And Year Ended March 31 2026.",
      "datetime": "06-May-2026",
      "details": "Venmax Drugs And Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2026 inter alia to consider and approve Audited Standalone Financial Results of the Company for the Quarter and Year ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "14-Apr-2026",
      "details": "Submission of Annual Secretarial Compliance Report for the year ended March 31 2026.",
      "source": "BSE"
    },
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "14-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Venmax Drugs and Pharmaceuticals Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1988PLC009102</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>0</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Priyanka Agarwal <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: venmaxdrugs@gmail.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Kummarikuntla Saibaba <br/> Designation: Chief Financial Officer <br/> EmailId: venmaxdrugs@gmail.com</div> </div> <div> <br/> Date: 14/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "14 May 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

When is the next results date for Venmax Drugs & Pharmaceuticals Ltd?

2026-05-07 23:16:30

The next results date for Venmax Drugs & Pharmaceuticals Ltd is scheduled for 14 May 2026....

Read full news article

Venmax Drugs & Pharmaceuticals Ltd is Rated Strong Sell

2026-04-30 10:10:20

Venmax Drugs & Pharmaceuticals Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 16 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Read full news article

Why is Venmax Drugs & Pharmaceuticals Ltd falling/rising?

2026-02-21 01:00:00

Short-Term Price Movement and Market Comparison

Venmax Drugs’ recent price action has been notably weaker compared to the benchmark Sensex. Over the past week, the stock has declined by 3.67%, while the Sensex gained 0.23%. Similarly, in the last month, Venmax Drugs marginally fell by 0.46%, whereas the Sensex rose by 0.77%. This underperformance is further emphasised by the stock’s three-day consecutive fall, during which it lost approximately 4.7% of its value. Such a trend indicates a short-term bearish sentiment among investors.

Despite these recent setbacks, the stock has delivered a positive return of 4.13% year-to-date, outperforming the Sensex which is down 2.82% in the same period. Over the last year, Venmax Drugs has appreciated by 6.96%, though this is sligh...

Read full news article

Venmax Drugs & Pharmaceuticals Downgraded to Strong Sell Amid Technical and Financial Concerns

2026-02-17 08:06:13

Venmax Drugs & Pharmaceuticals Ltd has been downgraded from a Sell to a Strong Sell rating as of 16 Feb 2026, reflecting deteriorating technical indicators and stagnant financial performance. The company’s Mojo Score has slipped to 17.0, signalling heightened risk for investors amid a challenging market environment and weakening fundamentals.

Read full news article

Venmax Drugs Falls 4.36%: 3 Key Factors Driving the Weekly Decline

2026-02-15 13:00:06

Key Events This Week

09 Feb: Q3 FY26 results reveal revenue growth but wafer-thin margins and governance concerns

10 Feb: Quality grade downgraded to below average with a Sell rating assigned

10 Feb: Mixed technical signals emerge amid flat financial performance

13 Feb: Week closes at Rs.26.97, down 4.36%, underperforming Sensex

Week Open

Rs.28.20

...

Read full news article

Venmax Drugs & Pharmaceuticals Ltd Downgraded to Sell Amidst Mixed Financial and Technical Signals

2026-02-10 08:05:57

Venmax Drugs & Pharmaceuticals Ltd has been assigned a Sell rating with a Mojo Score of 33.0, reflecting a downgrade from its previous ungraded status. This change, effective from 09 Feb 2026, is driven by deteriorating quality metrics, challenging financial trends, and a cautious technical outlook, signalling increased risk for investors in the Pharmaceuticals & Biotechnology sector.

Read full news article

Venmax Drugs & Pharmaceuticals Ltd Quality Grade Downgrade: A Detailed Fundamental Analysis

2026-02-10 08:00:09

Venmax Drugs & Pharmaceuticals Ltd has recently undergone a significant downgrade in its quality grading, shifting from a non-rated status to a below average rating as of 9 February 2026. This change reflects a reassessment of the company’s core financial health and operational consistency, raising concerns about its long-term investment appeal despite some strong sales growth. This article delves into the key financial metrics and business fundamentals that have influenced this downgrade, providing investors with a comprehensive understanding of the company’s current standing within the Pharmaceuticals & Biotechnology sector.

Read full news article

View All News